Mergers and acquisitions (M&A) in regulated industries require more than just financial due diligence-they demand a keen legal eye on licensing and regulatory compliance. Whether you're acquiring a transportation company regulated by the Department of Transportation (DOT), a biotech firm subject to Food and Drug Administration (FDA) oversight, or a business operating under state-specific licensure, overlooking license transferability and compliance can derail a transaction-or worse, expose you to penalties post-closing.
Contact us by either using the online form or calling us directly at 414-253-8500 for legal assistance with regulatory risk management in your transaction.
Understanding Industry Licensing Risks in M&A
Each industry operates under a unique set of licenses and regulatory frameworks. When a business transaction occurs-especially in regulated sectors-licenses may not transfer automatically. This creates a significant regulatory risk if not identified and addressed during deal structuring.
Common Industries with Licensing Concerns
-
Pharmaceutical and Biotech (FDA-Regulated)
-
Transportation and Logistics (DOT-Regulated)
-
Cannabis and Alcohol
-
Healthcare Facilities
-
Energy and Environmental Services
-
Professional Services (law, finance, engineering)
-
Franchises
-
Food and Beverage Manufacturing
Each comes with its own licensure, permitting, and ongoing compliance requirements that must be assessed.
FDA Licensing and Compliance in M&A
If your target company manufactures, distributes, or researches drugs, medical devices, or food products, FDA involvement is inevitable. Here's what must be reviewed:
Key FDA Considerations in a Transaction
-
Facility Registrations: FDA-registered facilities often must notify the FDA of ownership changes. These do not always transfer automatically.
-
Product Approvals (e.g., NDAs, PMAs): Ownership of FDA approvals must be carefully handled. The FDA may require updated documentation or new applications, especially in asset purchases.
-
Clinical Trials and Research: Transferring Investigational New Drug Applications (INDs) can be complicated and may require new submissions or amendments.
-
Warning Letters or Consent Decrees: Any enforcement history should be reviewed to assess compliance risk.
-
Labeling and Advertising Compliance: M&A due diligence should include review of marketing materials to ensure compliance with FDA advertising rules.
If not handled properly, acquiring an FDA-regulated company without updated filings can lead to product recalls, delays in production, or federal enforcement actions.
DOT Licensing and Safety Compliance in M&A
Transportation businesses-trucking companies, logistics providers, carriers-must comply with federal and state DOT requirements, including:
DOT M&A Considerations
-
Operating Authority (MC/FF Numbers): These are not typically transferable in an asset sale. In a stock sale, they may remain intact, but buyer assumes all compliance history.
-
Safety Ratings and Compliance Reviews: Prior compliance history (e.g., DOT audits or violations) transfers with the entity in a stock purchase.
-
Hazmat Licensing: Businesses transporting hazardous materials must hold valid DOT hazmat licenses and train employees accordingly.
-
USDOT Registration & UCR Filings: All must be kept current. A sale can trigger renewal obligations.
-
State-Level Requirements: Each state may impose separate registration and tax obligations for transportation entities.
Failing to address these regulatory issues during acquisition can result in operating authority revocation, fines, or delayed operations.
Asset Purchase vs. Stock Purchase: License Transferability
A central legal question in M&A is whether to structure the deal as a stock purchase or an asset purchase. Licensing concerns heavily influence this decision.
-
Stock Purchase: Licenses typically remain with the entity. This can be beneficial but means the buyer inherits any prior violations or regulatory baggage.
-
Asset Purchase: Licenses generally do not transfer, requiring reapplication. This structure can allow the buyer to start fresh but may introduce time delays and interim operating risks.
For example, a trucking company with a poor DOT safety record might be better acquired via asset sale to avoid inheriting liability, while a pharma company with rare FDA product approvals may necessitate a stock transaction to maintain continuity.
Due Diligence: Identifying Regulatory Red Flags
Legal due diligence should include a targeted license and compliance review, especially in regulated industries. Key steps include:
-
Obtain Copies of All Active Licenses and Permits
-
Review Correspondence with Regulatory Agencies (FDA, DOT, etc.)
-
Check for Expired, Suspended, or Revoked Licenses
-
Audit Training, Recordkeeping, and Internal Compliance Programs
-
Review Whether Any Approvals Are Personal or Entity-Specific
-
Confirm Ongoing Reporting Obligations and Inspection Schedules
This process often requires liaising with regulatory agencies or conducting Freedom of Information Act (FOIA) requests to uncover hidden risk.
State Licensing and Local Regulatory Issues
While federal agencies like the FDA and DOT regulate broad sectors, many businesses are also subject to state-level licensing and local permitting requirements. These are often overlooked in national transactions but can cause major operational delays post-closing.
Common Examples of State and Local License Triggers
-
Contractor or Building Permits
-
State Alcohol Beverage Licenses
-
Cannabis Dispensary Licenses (State-Issued and Non-Transferable)
-
Retail Seller's Permits
-
Professional Licenses (e.g., CPAs, engineers, real estate brokers)
Licensing boards typically do not allow license transfers. Instead, the buyer must reapply and demonstrate qualifications. This can delay operations, revenue recognition, or compliance certifications after acquisition.
Hidden Risks: Change of Ownership Notices & Re-Approvals
Many agencies-federal, state, and local-require advance notification of a change in ownership. If this step is missed, licenses may become void or unenforceable.
Examples:
-
Healthcare businesses may require a change-of-ownership (CHOW) application.
-
Pharmaceutical companies must notify the FDA regarding ownership of drug master files or product licenses.
-
DOT-licensed companies may have to update records within a specified time frame post-closing.
Failing to comply with CHOW procedures can result in:
-
Delayed contract enforcement
-
Loss of billing privileges
-
Regulatory fines
-
Suspension of business operations
Common Deal Terms That Address Licensing Risk
Experienced M&A attorneys often negotiate key protective terms into the purchase agreement to manage licensing and regulatory risk:
Clauses to Consider
-
Pre-Closing Covenants: Require the seller to maintain all licenses in good standing and avoid any regulatory action before closing.
-
Closing Conditions: Make the deal contingent on approval or reissuance of certain licenses.
-
Reps & Warranties: Include detailed representations about compliance status, past violations, and current licensure.
-
Indemnification: Shift risk of undisclosed violations or regulatory issues to the seller.
-
Holdbacks or Escrows: Set aside funds to cover potential fines or license re-issuance delays.
These protections are critical when dealing with regulated targets.
Post-Closing Integration Risks
After the deal closes, integration activities may trigger regulatory scrutiny. For example:
-
Rebranding can require re-submission of product labels to the FDA.
-
Consolidating operations could alter DOT safety ratings or reporting thresholds.
-
New executives may need to be disclosed to licensing agencies.
Your legal team should build a post-closing compliance checklist to ensure seamless integration and avoid violations.
Why Legal Counsel is Essential
Licensing and regulatory issues are often buried deep in the fine print, but they can make or break a deal. Having an attorney who understands industry-specific licensing structures can protect your business from:
-
Unintended noncompliance
-
Costly delays in operations
-
Fines or revocation of privileges
-
Post-closing lawsuits or indemnification claims
Legal guidance is especially important when navigating acquisitions involving:
-
FDA-regulated products
-
DOT-regulated transportation
-
Multi-state licensing structures
-
Cannabis, healthcare, or environmental permits
Contact an Attorney for Licensing Issues in M&A Transactions
Whether you're buying a healthcare facility, trucking company, or biotech firm, industry-specific licensing can present high-stakes regulatory challenges in mergers and acquisitions. The experienced attorneys at Heritage Law Office help clients structure deals, conduct regulatory due diligence, and minimize legal exposure across a wide range of sectors.
Contact us by calling 414-253-8500 or using our secure online form to schedule a consultation. Our legal team can help ensure your transaction stays compliant-before, during, and after the deal closes.
Frequently Asked Questions (FAQs)
1. What happens to FDA licenses during a business acquisition?
FDA licenses and approvals, such as New Drug Applications (NDAs) or facility registrations, typically do not transfer automatically during an acquisition-especially in asset purchases. In most cases, new ownership must notify the FDA and, in some situations, reapply for certain approvals or amend existing ones. It's critical to review product-specific regulations and submit appropriate filings to avoid disruptions.
2. Can DOT operating authority be transferred in a merger or acquisition?
DOT operating authority is not transferable in asset purchases. The acquiring entity must apply for new authority and meet all regulatory and insurance requirements. In stock purchases, the operating authority generally remains valid, but the new owner assumes all past safety ratings, violations, and compliance history.
3. What are the risks of ignoring change-of-ownership requirements?
Failing to notify licensing agencies of a change in ownership can invalidate licenses or permits. This may result in regulatory penalties, loss of operating privileges, or inability to bill government programs. Change-of-ownership filings are especially important in industries like healthcare, transportation, and manufacturing.
4. Are state-issued licenses transferrable during an acquisition?
In most cases, state-issued licenses are non-transferable, particularly in regulated professions and sectors like healthcare, cannabis, and construction. The buyer will need to apply for new licenses or permits. Failing to do so can result in business interruption or enforcement action from state regulators.
5. What type of due diligence should be done on licenses before an acquisition?
Thorough due diligence should include:
-
A complete inventory of all licenses and permits
-
A review of expiration dates and renewal status
-
Investigation of regulatory history or past violations
-
Identification of license transferability issues
-
Verification of any pending audits or enforcement actions
Legal professionals often work with regulatory consultants and agencies to confirm licensing compliance during the M&A process.